MBK-01
Phase 3Biologic
MBK-01 is one of 29 biologic programs targeting Diverticulitis. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
26 competitors in Clostridioides Difficile Infection
#DrugCompanyPhaseTrials
1Active Comparator
ModernaPhase 2
RBX2660
FerringPhase 3
VE303
VVedanta Biosciences, Inc.
Phase 3
MBK-01
MMikrobiomik Healthcare Company S.L.
Phase 3
Vancomycin or Fidaxomicin
SSejtterapia Kozpont Kft.
Phase 3
Dificlir
Merck & Co.Preclinical
EXL01
EExeliom Biosciences
Phase 2
Vancocin
HHikma Pharmaceuticals LLC
Preclinical
AZD5148
AstraZenecaPhase 2
ZINPLAVA
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diverticulitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MBK-01. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details